Simultaneously detects HCV core antigen and anti-HCV antibodies for more accurate screening
Transasia Bio-Medicals announced the launch of India’s first, high sensitivity testing kit for hepatitis C virus. Based on the latest method, the ErbaLisa HCV Gen 4 Ag+Ab kit, is India’s first and only indigenously developed 4th gen ELISA kit and has been evaluated by the National Institute of Biologicals (NIB).
ErbaLisa HCV Gen4 Ag+Ab kit is intended for the detection of HCV core antigen (viral protein) and anti-HCV antibodies, simultaneously, in human serum and plasma. It has a sensitivity of 100 per cent and a specificity of 99.67 per cent.
The simultaneous detection of antigen and antibodies with ErbaLisa HCV Gen4 Ag+Ab will greatly aid in screening HCV more accurately, as the window period for HCV detection will be reduced to less than 28 days.
“In the last two years, the focus has been on COVID-19. Needless to say, there are other infectious diseases too, that need immediate attention. Viral hepatitis continues to be a growing concern in India and is equated as a threat comparable to the big three communicable diseases – HIV/AIDS, Malaria and TB. It is crucial to screen blood donors for HCV. ErbaLisa HCV Gen4 Ag+Ab kit, on one hand, offers better and reliable screening of blood in blood banks before transfusion and on the other hand for the labs and patients, it allows an opportunity for early detection and better management of infection,” cited Suresh Vazirani, Founder CMD, Transasia-Erba International Group of Companies.
